#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1. Introduction
1-1	0-2	1.	_	_	_	_
1-2	3-15	Introduction	abstract	new	_	_

#Text=Human
2-1	16-21	Human	person	new	_	_

#Text=T-lymphotropic virus 1 ( HTLV-1 ) is a Deltaretrovirus , endemic in Japan , Caribbean , South America , Sub-Saharan Africa , and Melanesia .
3-1	22-36	T-lymphotropic	abstract|abstract[4]|abstract[5]	new|new[4]|new[5]	appos|appos|appos	3-5[0_5]|3-5[0_5]|3-5[0_5]
3-2	37-42	virus	abstract[4]|abstract[5]	new[4]|new[5]	_	_
3-3	43-44	1	abstract[5]	new[5]	_	_
3-4	45-46	(	_	_	_	_
3-5	47-53	HTLV-1	abstract	giv	coref	3-8[7_0]
3-6	54-55	)	_	_	_	_
3-7	56-58	is	_	_	_	_
3-8	59-60	a	abstract[7]	giv[7]	coref	4-1[0_7]
3-9	61-76	Deltaretrovirus	abstract[7]	giv[7]	_	_
3-10	77-78	,	_	_	_	_
3-11	79-86	endemic	_	_	_	_
3-12	87-89	in	_	_	_	_
3-13	90-95	Japan	place	new	_	_
3-14	96-97	,	_	_	_	_
3-15	98-107	Caribbean	place	new	_	_
3-16	108-109	,	_	_	_	_
3-17	110-115	South	place[10]	new[10]	_	_
3-18	116-123	America	place[10]	new[10]	_	_
3-19	124-125	,	_	_	_	_
3-20	126-137	Sub-Saharan	place[11]	new[11]	_	_
3-21	138-144	Africa	place[11]	new[11]	_	_
3-22	145-146	,	_	_	_	_
3-23	147-150	and	_	_	_	_
3-24	151-160	Melanesia	place	new	_	_
3-25	161-162	.	_	_	_	_

#Text=HTLV-1 is associated with several different types of diseases .
4-1	163-169	HTLV-1	abstract	giv	coref	7-34
4-2	170-172	is	_	_	_	_
4-3	173-183	associated	_	_	_	_
4-4	184-188	with	_	_	_	_
4-5	189-196	several	abstract[14]	new[14]	_	_
4-6	197-206	different	abstract[14]	new[14]	_	_
4-7	207-212	types	abstract[14]	new[14]	_	_
4-8	213-215	of	abstract[14]	new[14]	_	_
4-9	216-224	diseases	abstract[14]|abstract	new[14]|new	coref	6-24[29_0]
4-10	225-226	.	_	_	_	_

#Text=Adult T-cell leukemia/lymphoma ( ATLL ) develops in up to 5 % of infected people , and sometimes a chronic neurodegenerative inflammatory disease called HTLV-1-associated myelopathy ( HAM ) develops .
5-1	227-232	Adult	abstract[16]	new[16]	appos	5-5[0_16]
5-2	233-239	T-cell	abstract[16]	new[16]	_	_
5-3	240-257	leukemia/lymphoma	_	_	_	_
5-4	258-259	(	_	_	_	_
5-5	260-264	ATLL	abstract	giv	coref	18-15[133_0]
5-6	265-266	)	_	_	_	_
5-7	267-275	develops	_	_	_	_
5-8	276-278	in	_	_	_	_
5-9	279-281	up	_	_	_	_
5-10	282-284	to	_	_	_	_
5-11	285-286	5	quantity[18]	new[18]	_	_
5-12	287-288	%	quantity[18]	new[18]	_	_
5-13	289-291	of	quantity[18]	new[18]	_	_
5-14	292-300	infected	quantity[18]|person[19]	new[18]|new[19]	coref	6-2[23_19]
5-15	301-307	people	quantity[18]|person[19]	new[18]|new[19]	_	_
5-16	308-309	,	_	_	_	_
5-17	310-313	and	_	_	_	_
5-18	314-323	sometimes	abstract[20]	new[20]	coref	8-17[46_20]
5-19	324-325	a	abstract[20]	new[20]	_	_
5-20	326-333	chronic	abstract[20]	new[20]	_	_
5-21	334-351	neurodegenerative	abstract[20]	new[20]	_	_
5-22	352-364	inflammatory	abstract[20]	new[20]	_	_
5-23	365-372	disease	abstract[20]	new[20]	_	_
5-24	373-379	called	_	_	_	_
5-25	380-397	HTLV-1-associated	abstract[21]	new[21]	_	_
5-26	398-408	myelopathy	abstract[21]	new[21]	_	_
5-27	409-410	(	_	_	_	_
5-28	411-414	HAM	substance	new	coref	9-1
5-29	415-416	)	_	_	_	_
5-30	417-425	develops	_	_	_	_
5-31	426-427	.	_	_	_	_

#Text=Although a high percentage of people remain asymptomatic during their lifetime , a great number of infected people develop a large range of neurological diseases .
6-1	428-436	Although	_	_	_	_
6-2	437-438	a	person[23]	giv[23]	coref	6-17[27_23]
6-3	439-443	high	person[23]	giv[23]	_	_
6-4	444-454	percentage	person[23]	giv[23]	_	_
6-5	455-457	of	person[23]	giv[23]	_	_
6-6	458-464	people	person[23]	giv[23]	_	_
6-7	465-471	remain	_	_	_	_
6-8	472-484	asymptomatic	_	_	_	_
6-9	485-491	during	_	_	_	_
6-10	492-497	their	person|time[25]	acc|new[25]	_	_
6-11	498-506	lifetime	time[25]	new[25]	_	_
6-12	507-508	,	_	_	_	_
6-13	509-510	a	quantity[26]	new[26]	_	_
6-14	511-516	great	quantity[26]	new[26]	_	_
6-15	517-523	number	quantity[26]	new[26]	_	_
6-16	524-526	of	quantity[26]	new[26]	_	_
6-17	527-535	infected	quantity[26]|person[27]	new[26]|giv[27]	coref	19-6[139_27]
6-18	536-542	people	quantity[26]|person[27]	new[26]|giv[27]	_	_
6-19	543-550	develop	_	_	_	_
6-20	551-552	a	abstract[28]	new[28]	_	_
6-21	553-558	large	abstract[28]	new[28]	_	_
6-22	559-564	range	abstract[28]	new[28]	_	_
6-23	565-567	of	abstract[28]	new[28]	_	_
6-24	568-580	neurological	abstract[28]|abstract[29]	new[28]|giv[29]	coref	8-17[47_29]
6-25	581-589	diseases	abstract[28]|abstract[29]	new[28]|giv[29]	_	_
6-26	590-591	.	_	_	_	_

#Text=Other opportunistic-like infections , such as Strongyloidiasis , Norwegian scabies , infective dermatitis , as well as autoimmune syndromes , including rheumatoid arthritis and Sjögren ’s syndrome , have also been described among HTLV-1 carriers .
7-1	592-597	Other	abstract[30]	new[30]	_	_
7-2	598-616	opportunistic-like	abstract[30]	new[30]	_	_
7-3	617-627	infections	abstract[30]	new[30]	_	_
7-4	628-629	,	abstract[30]	new[30]	_	_
7-5	630-634	such	abstract[30]	new[30]	_	_
7-6	635-637	as	abstract[30]	new[30]	_	_
7-7	638-654	Strongyloidiasis	abstract[30]|substance	new[30]|new	_	_
7-8	655-656	,	abstract[30]	new[30]	_	_
7-9	657-666	Norwegian	abstract[30]|object[32]	new[30]|new[32]	_	_
7-10	667-674	scabies	abstract[30]|object[32]	new[30]|new[32]	_	_
7-11	675-676	,	abstract[30]	new[30]	_	_
7-12	677-686	infective	abstract[30]|abstract[33]	new[30]|new[33]	_	_
7-13	687-697	dermatitis	abstract[30]|abstract[33]	new[30]|new[33]	_	_
7-14	698-699	,	abstract[30]	new[30]	_	_
7-15	700-702	as	abstract[30]	new[30]	_	_
7-16	703-707	well	abstract[30]	new[30]	_	_
7-17	708-710	as	abstract[30]	new[30]	_	_
7-18	711-721	autoimmune	abstract[30]|abstract|abstract[35]	new[30]|new|new[35]	_	_
7-19	722-731	syndromes	abstract[30]|abstract[35]	new[30]|new[35]	_	_
7-20	732-733	,	abstract[30]|abstract[35]	new[30]|new[35]	_	_
7-21	734-743	including	abstract[30]|abstract[35]	new[30]|new[35]	_	_
7-22	744-754	rheumatoid	abstract[30]|abstract[35]|object|abstract[37]	new[30]|new[35]|new|new[37]	_	_
7-23	755-764	arthritis	abstract[30]|abstract[35]|abstract[37]	new[30]|new[35]|new[37]	_	_
7-24	765-768	and	abstract[30]|abstract[35]	new[30]|new[35]	_	_
7-25	769-776	Sjögren	abstract[30]|abstract[35]|person[38]|abstract[39]	new[30]|new[35]|new[38]|new[39]	coref|coref	9-23[62_39]|9-23[62_39]
7-26	777-779	’s	abstract[30]|abstract[35]|person[38]|abstract[39]	new[30]|new[35]|new[38]|new[39]	_	_
7-27	780-788	syndrome	abstract[30]|abstract[35]|abstract[39]	new[30]|new[35]|new[39]	_	_
7-28	789-790	,	_	_	_	_
7-29	791-795	have	_	_	_	_
7-30	796-800	also	_	_	_	_
7-31	801-805	been	_	_	_	_
7-32	806-815	described	_	_	_	_
7-33	816-821	among	_	_	_	_
7-34	822-828	HTLV-1	event|organization[41]	giv|new[41]	coref|coref	17-1|17-1
7-35	829-837	carriers	organization[41]	new[41]	_	_
7-36	838-839	.	_	_	_	_

#Text=In these patients , the clinical conditions appear to be the result of the interaction between the virus and the host susceptibility , leading to the abnormal functioning of immuno-modulatory mechanisms , cell proliferation , and inflammation .
8-1	840-842	In	_	_	_	_
8-2	843-848	these	person[42]	new[42]	coref	14-61[108_42]
8-3	849-857	patients	person[42]	new[42]	_	_
8-4	858-859	,	_	_	_	_
8-5	860-863	the	abstract[43]	new[43]	_	_
8-6	864-872	clinical	abstract[43]	new[43]	_	_
8-7	873-883	conditions	abstract[43]	new[43]	_	_
8-8	884-890	appear	_	_	_	_
8-9	891-893	to	_	_	_	_
8-10	894-896	be	_	_	_	_
8-11	897-900	the	abstract[44]	new[44]	_	_
8-12	901-907	result	abstract[44]	new[44]	_	_
8-13	908-910	of	abstract[44]	new[44]	_	_
8-14	911-914	the	abstract[44]|abstract[45]	new[44]|new[45]	_	_
8-15	915-926	interaction	abstract[44]|abstract[45]	new[44]|new[45]	_	_
8-16	927-934	between	abstract[44]|abstract[45]	new[44]|new[45]	_	_
8-17	935-938	the	abstract[44]|abstract[45]|abstract[46]|abstract[47]	new[44]|new[45]|giv[46]|giv[47]	coref|coref|coref|coref	13-18[88_46]|18-18[134_47]|13-18[88_46]|18-18[134_47]
8-18	939-944	virus	abstract[44]|abstract[45]|abstract[46]|abstract[47]	new[44]|new[45]|giv[46]|giv[47]	_	_
8-19	945-948	and	abstract[44]|abstract[45]|abstract[47]	new[44]|new[45]|giv[47]	_	_
8-20	949-952	the	abstract[44]|abstract[45]|abstract[47]|abstract[49]	new[44]|new[45]|giv[47]|new[49]	_	_
8-21	953-957	host	abstract[44]|abstract[45]|abstract[47]|person|abstract[49]	new[44]|new[45]|giv[47]|new|new[49]	coref	19-38[145_0]
8-22	958-972	susceptibility	abstract[44]|abstract[45]|abstract[47]|abstract[49]	new[44]|new[45]|giv[47]|new[49]	_	_
8-23	973-974	,	_	_	_	_
8-24	975-982	leading	_	_	_	_
8-25	983-985	to	_	_	_	_
8-26	986-989	the	abstract[50]	new[50]	_	_
8-27	990-998	abnormal	abstract[50]	new[50]	_	_
8-28	999-1010	functioning	abstract[50]	new[50]	_	_
8-29	1011-1013	of	abstract[50]	new[50]	_	_
8-30	1014-1031	immuno-modulatory	abstract[50]|abstract|abstract[52]	new[50]|new|new[52]	_	_
8-31	1032-1042	mechanisms	abstract[50]|abstract[52]	new[50]|new[52]	_	_
8-32	1043-1044	,	abstract[50]	new[50]	_	_
8-33	1045-1049	cell	abstract[50]|place|abstract[54]	new[50]|new|new[54]	coref|coref	15-8[111_54]|15-8[111_54]
8-34	1050-1063	proliferation	abstract[50]|abstract[54]	new[50]|new[54]	_	_
8-35	1064-1065	,	abstract[50]	new[50]	_	_
8-36	1066-1069	and	abstract[50]	new[50]	_	_
8-37	1070-1082	inflammation	abstract[50]|abstract	new[50]|new	_	_
8-38	1083-1084	.	_	_	_	_

#Text=HAM is a chronic progressive demyelinating disease that affects the spinal cord and the white matter of the brain , leading to a severe clinical syndrome due to the motor limitations that affect the lower limbs associated with the autonomic dysfunction .
9-1	1085-1088	HAM	abstract	giv	coref	9-3[58_0]
9-2	1089-1091	is	_	_	_	_
9-3	1092-1093	a	abstract[58]	giv[58]	coref	11-7[0_58]
9-4	1094-1101	chronic	abstract[58]	giv[58]	_	_
9-5	1102-1113	progressive	abstract[58]	giv[58]	_	_
9-6	1114-1127	demyelinating	abstract|abstract[58]	new|giv[58]	_	_
9-7	1128-1135	disease	abstract[58]	giv[58]	_	_
9-8	1136-1140	that	_	_	_	_
9-9	1141-1148	affects	_	_	_	_
9-10	1149-1152	the	object[59]	new[59]	_	_
9-11	1153-1159	spinal	object[59]	new[59]	_	_
9-12	1160-1164	cord	object[59]	new[59]	_	_
9-13	1165-1168	and	_	_	_	_
9-14	1169-1172	the	object[60]	new[60]	_	_
9-15	1173-1178	white	object[60]	new[60]	_	_
9-16	1179-1185	matter	object[60]	new[60]	_	_
9-17	1186-1188	of	object[60]	new[60]	_	_
9-18	1189-1192	the	object[60]|object[61]	new[60]|new[61]	_	_
9-19	1193-1198	brain	object[60]|object[61]	new[60]|new[61]	_	_
9-20	1199-1200	,	_	_	_	_
9-21	1201-1208	leading	_	_	_	_
9-22	1209-1211	to	_	_	_	_
9-23	1212-1213	a	abstract[62]	giv[62]	_	_
9-24	1214-1220	severe	abstract[62]	giv[62]	_	_
9-25	1221-1229	clinical	abstract[62]	giv[62]	_	_
9-26	1230-1238	syndrome	abstract[62]	giv[62]	_	_
9-27	1239-1242	due	abstract[62]	giv[62]	_	_
9-28	1243-1245	to	_	_	_	_
9-29	1246-1249	the	abstract[64]	new[64]	_	_
9-30	1250-1255	motor	object|abstract[64]	new|new[64]	_	_
9-31	1256-1267	limitations	abstract[64]	new[64]	_	_
9-32	1268-1272	that	_	_	_	_
9-33	1273-1279	affect	_	_	_	_
9-34	1280-1283	the	object[65]	new[65]	coref	11-18[76_65]
9-35	1284-1289	lower	object[65]	new[65]	_	_
9-36	1290-1295	limbs	object[65]	new[65]	_	_
9-37	1296-1306	associated	_	_	_	_
9-38	1307-1311	with	_	_	_	_
9-39	1312-1315	the	abstract[66]	new[66]	_	_
9-40	1316-1325	autonomic	abstract[66]	new[66]	_	_
9-41	1326-1337	dysfunction	abstract[66]	new[66]	_	_
9-42	1338-1339	.	_	_	_	_

#Text=The clinical picture begins and evolves insidiously , being difficult to establish when the first symptoms appeared .
10-1	1340-1343	The	abstract[67]	new[67]	_	_
10-2	1344-1352	clinical	abstract[67]	new[67]	_	_
10-3	1353-1360	picture	abstract[67]	new[67]	_	_
10-4	1361-1367	begins	_	_	_	_
10-5	1368-1371	and	_	_	_	_
10-6	1372-1379	evolves	_	_	_	_
10-7	1380-1391	insidiously	_	_	_	_
10-8	1392-1393	,	_	_	_	_
10-9	1394-1399	being	_	_	_	_
10-10	1400-1409	difficult	_	_	_	_
10-11	1410-1412	to	_	_	_	_
10-12	1413-1422	establish	_	_	_	_
10-13	1423-1427	when	_	_	_	_
10-14	1428-1431	the	abstract[68]	new[68]	coref	11-5[70_68]
10-15	1432-1437	first	abstract[68]	new[68]	_	_
10-16	1438-1446	symptoms	abstract[68]	new[68]	_	_
10-17	1447-1455	appeared	_	_	_	_
10-18	1456-1457	.	_	_	_	_

#Text=The main signs and symptoms of HAM may include gait disturbance , weakness , and stiffness of the lower limbs .
11-1	1458-1461	The	abstract[69]	new[69]	_	_
11-2	1462-1466	main	abstract[69]	new[69]	_	_
11-3	1467-1472	signs	abstract[69]	new[69]	_	_
11-4	1473-1476	and	_	_	_	_
11-5	1477-1485	symptoms	abstract[70]	giv[70]	coref	19-4[138_70]
11-6	1486-1488	of	abstract[70]	giv[70]	_	_
11-7	1489-1492	HAM	abstract[70]|abstract	giv[70]|giv	coref	12-5[78_0]
11-8	1493-1496	may	_	_	_	_
11-9	1497-1504	include	_	_	_	_
11-10	1505-1509	gait	abstract|abstract[73]	new|new[73]	_	_
11-11	1510-1521	disturbance	abstract[73]	new[73]	_	_
11-12	1522-1523	,	_	_	_	_
11-13	1524-1532	weakness	abstract	new	_	_
11-14	1533-1534	,	_	_	_	_
11-15	1535-1538	and	_	_	_	_
11-16	1539-1548	stiffness	abstract[75]	new[75]	_	_
11-17	1549-1551	of	abstract[75]	new[75]	_	_
11-18	1552-1555	the	abstract[75]|object[76]	new[75]|giv[76]	_	_
11-19	1556-1561	lower	abstract[75]|object[76]	new[75]|giv[76]	_	_
11-20	1562-1567	limbs	abstract[75]|object[76]	new[75]|giv[76]	_	_
11-21	1568-1569	.	_	_	_	_

#Text=The first manifestations of the disease occur in the fourth decade of life and there is a 2:1 woman/man ratio .
12-1	1570-1573	The	event[77]	new[77]	_	_
12-2	1574-1579	first	event[77]	new[77]	_	_
12-3	1580-1594	manifestations	event[77]	new[77]	_	_
12-4	1595-1597	of	event[77]	new[77]	_	_
12-5	1598-1601	the	event[77]|abstract[78]	new[77]|giv[78]	coref	14-5[0_78]
12-6	1602-1609	disease	event[77]|abstract[78]	new[77]|giv[78]	_	_
12-7	1610-1615	occur	_	_	_	_
12-8	1616-1618	in	_	_	_	_
12-9	1619-1622	the	time[79]	new[79]	_	_
12-10	1623-1629	fourth	time[79]	new[79]	_	_
12-11	1630-1636	decade	time[79]	new[79]	_	_
12-12	1637-1639	of	time[79]	new[79]	_	_
12-13	1640-1644	life	time[79]|time	new[79]|new	coref	13-1[84_0]
12-14	1645-1648	and	_	_	_	_
12-15	1649-1654	there	_	_	_	_
12-16	1655-1657	is	_	_	_	_
12-17	1658-1659	a	abstract[82]	new[82]	_	_
12-18	1660-1663	2:1	abstract[82]	new[82]	_	_
12-19	1664-1673	woman/man	person|abstract[82]	new|new[82]	_	_
12-20	1674-1679	ratio	abstract[82]	new[82]	_	_
12-21	1680-1681	.	_	_	_	_

#Text=The incubation period differs from patient to patient and seems to be shorter in the cases where the virus was acquired through blood transfusion .
13-1	1682-1685	The	time[84]	giv[84]	_	_
13-2	1686-1696	incubation	abstract|time[84]	new|giv[84]	_	_
13-3	1697-1703	period	time[84]	giv[84]	_	_
13-4	1704-1711	differs	_	_	_	_
13-5	1712-1716	from	_	_	_	_
13-6	1717-1724	patient	person	new	_	_
13-7	1725-1727	to	_	_	_	_
13-8	1728-1735	patient	person	new	_	_
13-9	1736-1739	and	_	_	_	_
13-10	1740-1745	seems	_	_	_	_
13-11	1746-1748	to	_	_	_	_
13-12	1749-1751	be	_	_	_	_
13-13	1752-1759	shorter	_	_	_	_
13-14	1760-1762	in	_	_	_	_
13-15	1763-1766	the	abstract[87]	new[87]	_	_
13-16	1767-1772	cases	abstract[87]	new[87]	_	_
13-17	1773-1778	where	_	_	_	_
13-18	1779-1782	the	abstract[88]	giv[88]	coref	14-48[105_88]
13-19	1783-1788	virus	abstract[88]	giv[88]	_	_
13-20	1789-1792	was	_	_	_	_
13-21	1793-1801	acquired	_	_	_	_
13-22	1802-1809	through	_	_	_	_
13-23	1810-1815	blood	substance|object[90]	new|new[90]	coref|coref	14-52[106_0]|14-52[106_0]
13-24	1816-1827	transfusion	object[90]	new[90]	_	_
13-25	1828-1829	.	_	_	_	_

#Text=Two important aspects of HAM development have been reported , including the efficiency of the cellular immune response and the rate of spontaneous expression of the viral antigen , due to the numerous immunological alterations , mediated mainly by the expression of Tax ( regulatory protein of the virus ) in the peripheral blood and in the cerebrospinal fluid of patients with HAM .
14-1	1830-1833	Two	abstract[91]	new[91]	_	_
14-2	1834-1843	important	abstract[91]	new[91]	_	_
14-3	1844-1851	aspects	abstract[91]	new[91]	_	_
14-4	1852-1854	of	abstract[91]	new[91]	_	_
14-5	1855-1858	HAM	abstract[91]|substance|event[93]	new[91]|giv|new[93]	coref|coref	14-63|14-63
14-6	1859-1870	development	abstract[91]|event[93]	new[91]|new[93]	_	_
14-7	1871-1875	have	_	_	_	_
14-8	1876-1880	been	_	_	_	_
14-9	1881-1889	reported	_	_	_	_
14-10	1890-1891	,	_	_	_	_
14-11	1892-1901	including	_	_	_	_
14-12	1902-1905	the	abstract[94]	new[94]	_	_
14-13	1906-1916	efficiency	abstract[94]	new[94]	_	_
14-14	1917-1919	of	abstract[94]	new[94]	_	_
14-15	1920-1923	the	abstract[94]|abstract[96]|abstract[97]	new[94]|new[96]|new[97]	coref|coref|coref|coref	17-14[125_96]|20-31[157_97]|17-14[125_96]|20-31[157_97]
14-16	1924-1932	cellular	abstract[94]|abstract[96]|abstract[97]	new[94]|new[96]|new[97]	_	_
14-17	1933-1939	immune	abstract[94]|abstract|abstract[96]|abstract[97]	new[94]|new|new[96]|new[97]	coref	16-11
14-18	1940-1948	response	abstract[94]|abstract[96]|abstract[97]	new[94]|new[96]|new[97]	_	_
14-19	1949-1952	and	abstract[94]|abstract[97]	new[94]|new[97]	_	_
14-20	1953-1956	the	abstract[94]|abstract[97]|abstract[98]	new[94]|new[97]|new[98]	_	_
14-21	1957-1961	rate	abstract[94]|abstract[97]|abstract[98]	new[94]|new[97]|new[98]	_	_
14-22	1962-1964	of	abstract[94]|abstract[97]|abstract[98]	new[94]|new[97]|new[98]	_	_
14-23	1965-1976	spontaneous	abstract[94]|abstract[97]|abstract[98]|abstract[99]	new[94]|new[97]|new[98]|new[99]	_	_
14-24	1977-1987	expression	abstract[94]|abstract[97]|abstract[98]|abstract[99]	new[94]|new[97]|new[98]|new[99]	_	_
14-25	1988-1990	of	abstract[94]|abstract[97]|abstract[98]|abstract[99]	new[94]|new[97]|new[98]|new[99]	_	_
14-26	1991-1994	the	abstract[94]|abstract[97]|abstract[98]|abstract[99]|abstract[100]	new[94]|new[97]|new[98]|new[99]|new[100]	_	_
14-27	1995-2000	viral	abstract[94]|abstract[97]|abstract[98]|abstract[99]|abstract[100]	new[94]|new[97]|new[98]|new[99]|new[100]	_	_
14-28	2001-2008	antigen	abstract[94]|abstract[97]|abstract[98]|abstract[99]|abstract[100]	new[94]|new[97]|new[98]|new[99]|new[100]	_	_
14-29	2009-2010	,	_	_	_	_
14-30	2011-2014	due	_	_	_	_
14-31	2015-2017	to	_	_	_	_
14-32	2018-2021	the	abstract[101]	new[101]	_	_
14-33	2022-2030	numerous	abstract[101]	new[101]	_	_
14-34	2031-2044	immunological	abstract[101]	new[101]	_	_
14-35	2045-2056	alterations	abstract[101]	new[101]	_	_
14-36	2057-2058	,	_	_	_	_
14-37	2059-2067	mediated	_	_	_	_
14-38	2068-2074	mainly	_	_	_	_
14-39	2075-2077	by	_	_	_	_
14-40	2078-2081	the	abstract[102]	new[102]	_	_
14-41	2082-2092	expression	abstract[102]	new[102]	_	_
14-42	2093-2095	of	abstract[102]	new[102]	_	_
14-43	2096-2099	Tax	abstract[102]|abstract	new[102]|new	appos	14-45[104_0]
14-44	2100-2101	(	_	_	_	_
14-45	2102-2112	regulatory	abstract[104]	giv[104]	_	_
14-46	2113-2120	protein	abstract[104]	giv[104]	_	_
14-47	2121-2123	of	abstract[104]	giv[104]	_	_
14-48	2124-2127	the	abstract[104]|abstract[105]	giv[104]|giv[105]	_	_
14-49	2128-2133	virus	abstract[104]|abstract[105]	giv[104]|giv[105]	_	_
14-50	2134-2135	)	_	_	_	_
14-51	2136-2138	in	_	_	_	_
14-52	2139-2142	the	substance[106]	giv[106]	_	_
14-53	2143-2153	peripheral	substance[106]	giv[106]	_	_
14-54	2154-2159	blood	substance[106]	giv[106]	_	_
14-55	2160-2163	and	_	_	_	_
14-56	2164-2166	in	_	_	_	_
14-57	2167-2170	the	substance[107]	new[107]	_	_
14-58	2171-2184	cerebrospinal	substance[107]	new[107]	_	_
14-59	2185-2190	fluid	substance[107]	new[107]	_	_
14-60	2191-2193	of	substance[107]	new[107]	_	_
14-61	2194-2202	patients	substance[107]|person[108]	new[107]|giv[108]	_	_
14-62	2203-2207	with	substance[107]|person[108]	new[107]|giv[108]	_	_
14-63	2208-2211	HAM	substance[107]|person[108]|abstract	new[107]|giv[108]|giv	coref	18-24
14-64	2212-2213	.	_	_	_	_

#Text=In order to control HTLV-1 replication and the proliferation of infected cells , CD8+
15-1	2214-2216	In	_	_	_	_
15-2	2217-2222	order	_	_	_	_
15-3	2223-2225	to	_	_	_	_
15-4	2226-2233	control	_	_	_	_
15-5	2234-2240	HTLV-1	abstract[110]	new[110]	_	_
15-6	2241-2252	replication	abstract[110]	new[110]	_	_
15-7	2253-2256	and	_	_	_	_
15-8	2257-2260	the	abstract[111]	giv[111]	_	_
15-9	2261-2274	proliferation	abstract[111]	giv[111]	_	_
15-10	2275-2277	of	abstract[111]	giv[111]	_	_
15-11	2278-2286	infected	abstract[111]|object[112]	giv[111]|new[112]	appos	15-14[0_112]
15-12	2287-2292	cells	abstract[111]|object[112]	giv[111]|new[112]	_	_
15-13	2293-2294	,	_	_	_	_
15-14	2295-2299	CD8+	object	giv	coref	17-4[123_0]

#Text=T lymphocytes mediate the main defense strategy of the host immune system .
16-1	2300-2301	T	person|place[115]	new|new[115]	coref|coref	17-5|17-5
16-2	2302-2313	lymphocytes	place[115]	new[115]	_	_
16-3	2314-2321	mediate	_	_	_	_
16-4	2322-2325	the	abstract[117]	new[117]	_	_
16-5	2326-2330	main	abstract[117]	new[117]	_	_
16-6	2331-2338	defense	abstract|abstract[117]	new|new[117]	_	_
16-7	2339-2347	strategy	abstract[117]	new[117]	_	_
16-8	2348-2350	of	abstract[117]	new[117]	_	_
16-9	2351-2354	the	abstract[117]|abstract[119]	new[117]|new[119]	coref	17-20[127_119]
16-10	2355-2359	host	abstract[117]|abstract[119]	new[117]|new[119]	_	_
16-11	2360-2366	immune	abstract[117]|abstract|abstract[119]	new[117]|giv|new[119]	coref	17-22
16-12	2367-2373	system	abstract[117]|abstract[119]	new[117]|new[119]	_	_
16-13	2374-2375	.	_	_	_	_

#Text=HTLV-1 infects mainly CD4+ T cells , which are the central regulators of the acquired immune response , deregulating the host immune system .
17-1	2376-2382	HTLV-1	abstract	giv	coref	18-6
17-2	2383-2390	infects	_	_	_	_
17-3	2391-2397	mainly	_	_	_	_
17-4	2398-2402	CD4+	substance|object[123]	new|giv[123]	coref|coref|coref|coref	18-8|18-8[132_123]|18-8|18-8[132_123]
17-5	2403-2404	T	person|object[123]	giv|giv[123]	coref	18-9
17-6	2405-2410	cells	object[123]	giv[123]	_	_
17-7	2411-2412	,	_	_	_	_
17-8	2413-2418	which	_	_	_	_
17-9	2419-2422	are	_	_	_	_
17-10	2423-2426	the	substance[124]	new[124]	_	_
17-11	2427-2434	central	substance[124]	new[124]	_	_
17-12	2435-2445	regulators	substance[124]	new[124]	_	_
17-13	2446-2448	of	substance[124]	new[124]	_	_
17-14	2449-2452	the	substance[124]|abstract[125]	new[124]|giv[125]	coref	20-31[156_125]
17-15	2453-2461	acquired	substance[124]|abstract[125]	new[124]|giv[125]	_	_
17-16	2462-2468	immune	substance[124]|abstract[125]	new[124]|giv[125]	_	_
17-17	2469-2477	response	substance[124]|abstract[125]	new[124]|giv[125]	_	_
17-18	2478-2479	,	_	_	_	_
17-19	2480-2492	deregulating	_	_	_	_
17-20	2493-2496	the	abstract[127]	giv[127]	coref	20-54[166_127]
17-21	2497-2501	host	abstract[127]	giv[127]	_	_
17-22	2502-2508	immune	abstract|abstract[127]	giv|giv[127]	_	_
17-23	2509-2515	system	abstract[127]	giv[127]	_	_
17-24	2516-2517	.	_	_	_	_

#Text=To establish persistent infection , HTLV-1 deregulates CD4+ T cells , sometimes leading to ATLL or to chronic inflammatory diseases , such as HAM and uveitis .
18-1	2518-2520	To	_	_	_	_
18-2	2521-2530	establish	_	_	_	_
18-3	2531-2541	persistent	abstract[128]	new[128]	coref	19-48[149_128]
18-4	2542-2551	infection	abstract[128]	new[128]	_	_
18-5	2552-2553	,	_	_	_	_
18-6	2554-2560	HTLV-1	place	giv	coref	19-48
18-7	2561-2572	deregulates	_	_	_	_
18-8	2573-2577	CD4+	substance|object[132]	giv|giv[132]	_	_
18-9	2578-2579	T	person|object[132]	giv|giv[132]	_	_
18-10	2580-2585	cells	object[132]	giv[132]	_	_
18-11	2586-2587	,	_	_	_	_
18-12	2588-2597	sometimes	_	_	_	_
18-13	2598-2605	leading	_	_	_	_
18-14	2606-2608	to	_	_	_	_
18-15	2609-2613	ATLL	abstract[133]	giv[133]	_	_
18-16	2614-2616	or	abstract[133]	giv[133]	_	_
18-17	2617-2619	to	abstract[133]	giv[133]	_	_
18-18	2620-2627	chronic	abstract[133]|abstract[134]	giv[133]|giv[134]	coref	19-20[142_134]
18-19	2628-2640	inflammatory	abstract[133]|abstract[134]	giv[133]|giv[134]	_	_
18-20	2641-2649	diseases	abstract[133]|abstract[134]	giv[133]|giv[134]	_	_
18-21	2650-2651	,	abstract[133]	giv[133]	_	_
18-22	2652-2656	such	abstract[133]	giv[133]	_	_
18-23	2657-2659	as	abstract[133]	giv[133]	_	_
18-24	2660-2663	HAM	abstract[133]|substance	giv[133]|giv	_	_
18-25	2664-2667	and	abstract[133]	giv[133]	_	_
18-26	2668-2675	uveitis	abstract[133]|abstract	giv[133]|new	_	_
18-27	2676-2677	.	_	_	_	_

#Text=The absence of symptoms in most of the infected people raises the question of the multiple etiological roles of the virus-associated diseases and some of the interesting questions still unanswered includes : does the immunogenic characteristics of the host contribute to the upsurge of symptoms associated with HTLV-1 infection ?
19-1	2678-2681	The	abstract[137]	new[137]	_	_
19-2	2682-2689	absence	abstract[137]	new[137]	_	_
19-3	2690-2692	of	abstract[137]	new[137]	_	_
19-4	2693-2701	symptoms	abstract[137]|abstract[138]	new[137]|giv[138]	coref	19-45[0_138]
19-5	2702-2704	in	abstract[137]|abstract[138]	new[137]|giv[138]	_	_
19-6	2705-2709	most	abstract[137]|abstract[138]|person[139]	new[137]|giv[138]|giv[139]	_	_
19-7	2710-2712	of	person[139]	giv[139]	_	_
19-8	2713-2716	the	person[139]	giv[139]	_	_
19-9	2717-2725	infected	person[139]	giv[139]	_	_
19-10	2726-2732	people	person[139]	giv[139]	_	_
19-11	2733-2739	raises	_	_	_	_
19-12	2740-2743	the	abstract[140]	new[140]	_	_
19-13	2744-2752	question	abstract[140]	new[140]	_	_
19-14	2753-2755	of	abstract[140]	new[140]	_	_
19-15	2756-2759	the	abstract[140]|abstract[141]	new[140]|new[141]	_	_
19-16	2760-2768	multiple	abstract[140]|abstract[141]	new[140]|new[141]	_	_
19-17	2769-2780	etiological	abstract[140]|abstract[141]	new[140]|new[141]	_	_
19-18	2781-2786	roles	abstract[140]|abstract[141]	new[140]|new[141]	_	_
19-19	2787-2789	of	abstract[140]|abstract[141]	new[140]|new[141]	_	_
19-20	2790-2793	the	abstract[140]|abstract[141]|abstract[142]	new[140]|new[141]|giv[142]	_	_
19-21	2794-2810	virus-associated	abstract[140]|abstract[141]|abstract[142]	new[140]|new[141]|giv[142]	_	_
19-22	2811-2819	diseases	abstract[140]|abstract[141]|abstract[142]	new[140]|new[141]|giv[142]	_	_
19-23	2820-2823	and	abstract[140]|abstract[141]	new[140]|new[141]	_	_
19-24	2824-2828	some	abstract[140]|abstract[141]	new[140]|new[141]	_	_
19-25	2829-2831	of	abstract[140]|abstract[141]	new[140]|new[141]	_	_
19-26	2832-2835	the	abstract[140]|abstract[141]|abstract[143]	new[140]|new[141]|new[143]	_	_
19-27	2836-2847	interesting	abstract[140]|abstract[141]|abstract[143]	new[140]|new[141]|new[143]	_	_
19-28	2848-2857	questions	abstract[140]|abstract[141]|abstract[143]	new[140]|new[141]|new[143]	_	_
19-29	2858-2863	still	abstract[140]|abstract[141]|abstract[143]	new[140]|new[141]|new[143]	_	_
19-30	2864-2874	unanswered	abstract[140]|abstract[141]|abstract[143]	new[140]|new[141]|new[143]	_	_
19-31	2875-2883	includes	_	_	_	_
19-32	2884-2885	:	_	_	_	_
19-33	2886-2890	does	_	_	_	_
19-34	2891-2894	the	abstract[144]	new[144]	_	_
19-35	2895-2906	immunogenic	abstract[144]	new[144]	_	_
19-36	2907-2922	characteristics	abstract[144]	new[144]	_	_
19-37	2923-2925	of	abstract[144]	new[144]	_	_
19-38	2926-2929	the	abstract[144]|person[145]	new[144]|giv[145]	coref	20-27[155_145]
19-39	2930-2934	host	abstract[144]|person[145]	new[144]|giv[145]	_	_
19-40	2935-2945	contribute	_	_	_	_
19-41	2946-2948	to	_	_	_	_
19-42	2949-2952	the	abstract[146]	new[146]	_	_
19-43	2953-2960	upsurge	abstract[146]	new[146]	_	_
19-44	2961-2963	of	abstract[146]	new[146]	_	_
19-45	2964-2972	symptoms	abstract[146]|abstract	new[146]|giv	_	_
19-46	2973-2983	associated	_	_	_	_
19-47	2984-2988	with	_	_	_	_
19-48	2989-2995	HTLV-1	object|abstract[149]	giv|giv[149]	coref|coref|coref|coref	20-35|20-35[159_149]|20-35|20-35[159_149]
19-49	2996-3005	infection	abstract[149]	giv[149]	_	_
19-50	3006-3007	?	_	_	_	_

#Text=The present manuscript presents the most relevant published results from several laboratories , including ours over the years regarding the associations between the genetic variations of the host related to the immune response and HTLV-1 infection , particularly those showing the close relationship between HTLV-1 infection and single nucleotide polymorphisms in genes of the immune system .
20-1	3008-3011	The	object[150]	new[150]	_	_
20-2	3012-3019	present	object[150]	new[150]	_	_
20-3	3020-3030	manuscript	object[150]	new[150]	_	_
20-4	3031-3039	presents	_	_	_	_
20-5	3040-3043	the	abstract[151]	new[151]	_	_
20-6	3044-3048	most	abstract[151]	new[151]	_	_
20-7	3049-3057	relevant	abstract[151]	new[151]	_	_
20-8	3058-3067	published	abstract[151]	new[151]	_	_
20-9	3068-3075	results	abstract[151]	new[151]	_	_
20-10	3076-3080	from	abstract[151]	new[151]	_	_
20-11	3081-3088	several	abstract[151]|place[152]	new[151]|new[152]	_	_
20-12	3089-3101	laboratories	abstract[151]|place[152]	new[151]|new[152]	_	_
20-13	3102-3103	,	_	_	_	_
20-14	3104-3113	including	_	_	_	_
20-15	3114-3118	ours	_	_	_	_
20-16	3119-3123	over	_	_	_	_
20-17	3124-3127	the	_	_	_	_
20-18	3128-3133	years	_	_	_	_
20-19	3134-3143	regarding	_	_	_	_
20-20	3144-3147	the	abstract[153]	new[153]	_	_
20-21	3148-3160	associations	abstract[153]	new[153]	_	_
20-22	3161-3168	between	abstract[153]	new[153]	_	_
20-23	3169-3172	the	abstract[153]|abstract[154]	new[153]|new[154]	_	_
20-24	3173-3180	genetic	abstract[153]|abstract[154]	new[153]|new[154]	_	_
20-25	3181-3191	variations	abstract[153]|abstract[154]	new[153]|new[154]	_	_
20-26	3192-3194	of	abstract[153]|abstract[154]	new[153]|new[154]	_	_
20-27	3195-3198	the	abstract[153]|abstract[154]|person[155]	new[153]|new[154]|giv[155]	_	_
20-28	3199-3203	host	abstract[153]|abstract[154]|person[155]	new[153]|new[154]|giv[155]	_	_
20-29	3204-3211	related	_	_	_	_
20-30	3212-3214	to	_	_	_	_
20-31	3215-3218	the	abstract[156]|abstract[157]	giv[156]|giv[157]	_	_
20-32	3219-3225	immune	abstract[156]|abstract[157]	giv[156]|giv[157]	_	_
20-33	3226-3234	response	abstract[156]|abstract[157]	giv[156]|giv[157]	_	_
20-34	3235-3238	and	abstract[157]	giv[157]	_	_
20-35	3239-3245	HTLV-1	abstract[157]|object|abstract[159]	giv[157]|giv|giv[159]	coref|coref|coref|coref	20-45|20-45[162_159]|20-45|20-45[162_159]
20-36	3246-3255	infection	abstract[157]|abstract[159]	giv[157]|giv[159]	_	_
20-37	3256-3257	,	_	_	_	_
20-38	3258-3270	particularly	_	_	_	_
20-39	3271-3276	those	_	_	_	_
20-40	3277-3284	showing	_	_	_	_
20-41	3285-3288	the	abstract[160]	new[160]	_	_
20-42	3289-3294	close	abstract[160]	new[160]	_	_
20-43	3295-3307	relationship	abstract[160]	new[160]	_	_
20-44	3308-3315	between	abstract[160]	new[160]	_	_
20-45	3316-3322	HTLV-1	abstract[160]|object|abstract[162]	new[160]|giv|giv[162]	_	_
20-46	3323-3332	infection	abstract[160]|abstract[162]	new[160]|giv[162]	_	_
20-47	3333-3336	and	abstract[160]	new[160]	_	_
20-48	3337-3343	single	abstract[160]|abstract[164]	new[160]|new[164]	_	_
20-49	3344-3354	nucleotide	abstract[160]|place|abstract[164]	new[160]|new|new[164]	_	_
20-50	3355-3368	polymorphisms	abstract[160]|abstract[164]	new[160]|new[164]	_	_
20-51	3369-3371	in	abstract[160]|abstract[164]	new[160]|new[164]	_	_
20-52	3372-3377	genes	abstract[160]|abstract[164]|abstract[165]	new[160]|new[164]|new[165]	_	_
20-53	3378-3380	of	abstract[160]|abstract[164]|abstract[165]	new[160]|new[164]|new[165]	_	_
20-54	3381-3384	the	abstract[160]|abstract[164]|abstract[165]|abstract[166]	new[160]|new[164]|new[165]|giv[166]	_	_
20-55	3385-3391	immune	abstract[160]|abstract[164]|abstract[165]|abstract[166]	new[160]|new[164]|new[165]|giv[166]	_	_
20-56	3392-3398	system	abstract[160]|abstract[164]|abstract[165]|abstract[166]	new[160]|new[164]|new[165]|giv[166]	_	_
20-57	3399-3400	.	_	_	_	_
